← Leaderboards
Robert F Siliciano
Johns Hopkins University
$70,514,274
Attributed
$92,282,083
Total exposure
19
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $11.3M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$107,126,572 · 21
By mechanism
T32$35,037,394 · 1
UM1$32,651,713 · 2
P01$20,100,555 · 7
R01$7,516,379 · 4
R37$3,459,236 · 2
U19$3,045,413 · 1
Top collaborators
- Luis J. Montaner6 shared
- Janice Ellen Clements5 shared
- Joseph L Mankowski5 shared
- James L Riley5 shared
- Drew Weissman1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Robert H Gilman$35,342,766
- Anne M Codori$784
- Steven R Kleeberger$929,417
- Massimo Caputi$2,814,988
- Jason Brandt$1,605,303
Others in their field
Top investigators on “Viral”
- Lawrence Corey · Fred Hutchinson Cancer Center$466,994,927
- David Heimbrook · Leidos Biomedical Research, Inc.$366,090,791
- Daniel R Kuritzkes · Brigham And Women'S Hospital$267,074,199
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$252,763,614
- Judith S. Currier · University Of California Los Angeles$185,434,785
- Constance Ann Benson · University Of California, San Diego$165,517,633
Research focus
ViralHiv-1CellsInfectionCd4 Positive T LymphocytesVirusRestViremiaPlasmaHiv InfectionsResearch PersonnelBloodDesignAffectAntiretroviral TherapyPharmaceutical PreparationsProvirusesMutationInsightCharacteristicsInterruptionScientistPersonsMacaca
Grant awards (113)
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$5,626,081
UM1 · FY2025 · AI
Individualized HIV Curative Combination Strategy against Persistent HIV on ART$3,568,644
UM1 · FY2025 · AI
Understanding reservoir dynamics through analysis of viral decay processes$1,573,078
P01 · FY2025 · AI · contact PI
Project 1: Analysis of 2nd phase decay in persons living with HIV$511,768
P01 · FY2025 · AI · contact PI
Administrative Core$15,939
P01 · FY2025 · AI · contact PI
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$5,736,593
UM1 · FY2024 · AI
Understanding reservoir dynamics through analysis of viral decay processes$1,573,078
P01 · FY2024 · AI · contact PI
Project 1: Analysis of 2nd phase decay in persons living with HIV$514,392
P01 · FY2024 · AI · contact PI
Administrative Core$13,315
P01 · FY2024 · AI · contact PI
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$5,780,735
UM1 · FY2023 · AI
Understanding reservoir dynamics through analysis of viral decay processes$1,573,078
P01 · FY2023 · AI · contact PI
Host and viral genomic determinants of HIV latent reservoir size and characteristics in individuals with substance use disorders$834,052
R33 · FY2023 · DA · contact PI
Project 1: Analysis of 2nd phase decay in persons living with HIV$514,418
P01 · FY2023 · AI · contact PI
Administrative Core$13,311
P01 · FY2023 · AI · contact PI
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$5,839,685
UM1 · FY2022 · AI
Understanding reservoir dynamics through analysis of viral decay processes$1,604,953
P01 · FY2022 · AI · contact PI
Host and viral genomic determinants of HIV latent reservoir size and characteristics in individuals with substance use disorders$843,854
R33 · FY2022 · DA · contact PI
Administrative Core$401,239
P01 · FY2022 · AI · contact PI
Project 1: Analysis of 2nd phase decay in persons living with HIV$401,238
P01 · FY2022 · AI · contact PI
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$6,099,975
UM1 · FY2021 · AI
Modeling HIV Rebound: Role of SIVmac251 Functional Reservoirs and Biomarkers of Reactivation$1,631,072
P01 · FY2021 · AI
Project 2 - Identification of the source of viral rebound using SIV proviral genome analysis$337,770
P01 · FY2021 · AI · contact PI
Modeling HIV Rebound: Role of SIVmac251 Functional Reservoirs and Biomarkers of Reactivation$1,957,980
P01 · FY2020 · AI
Host and viral genomic determinants of HIV latent reservoir size and characteristics in individuals with substance use disorders$903,625
R61 · FY2020 · DA · contact PI
Project 2 - Identification of the source of viral rebound using SIV proviral genome analysis$337,122
P01 · FY2020 · AI · contact PI
Modeling HIV Rebound: Role of SIVmac251 Functional Reservoirs and Biomarkers of Reactivation$1,672,200
P01 · FY2019 · AI
Host and viral genomic determinants of HIV latent reservoir size and characteristics in individuals with substance use disorders$908,958
R61 · FY2019 · DA · contact PI
Project 2 - Identification of the source of viral rebound using SIV proviral genome analysis$337,120
P01 · FY2019 · AI · contact PI
Modeling HIV Rebound: Role of SIVmac251 Functional Reservoirs and Biomarkers of Reactivation$1,630,865
P01 · FY2018 · AI
Host and viral genomic determinants of HIV latent reservoir size and characteristics in individuals with substance use disorders$950,298
R61 · FY2018 · DA · contact PI
Project 2 - Identification of the source of viral rebound using SIV proviral genome analysis$337,120
P01 · FY2018 · AI · contact PI
Modeling HIV Rebound: Role of SIVmac251 Functional Reservoirs and Biomarkers of Reactivation$1,628,185
P01 · FY2017 · AI
Project 2 - Identification of the source of viral rebound using SIV proviral genome analysis$330,165
P01 · FY2017 · AI · contact PI
Significance of Low Level Viremia in Patients on HAART$243,000
R37 · FY2016 · AI · contact PI
Medical Scientist Training Program$2,024,544
T32 · FY2015 · GM · contact PI
Define the sources of persistent HIV production$410,237
U19 · FY2015 · AI · contact PI
Medical Scientist Training Program$253,070
T32 · FY2015 · GM · contact PI
Significance of Low Level Viremia in Patients on HAART$243,000
R37 · FY2015 · AI · contact PI
Medical Scientist Training Program$2,032,393
T32 · FY2014 · GM · contact PI
Define the sources of persistent HIV production$557,870
U19 · FY2014 · AI · contact PI
Significance of Low Level Viremia in Patients on HAART$243,000
R37 · FY2014 · AI · contact PI
Medical Scientist Training Program$100,268
T32 · FY2014 · GM · contact PI
Medical Scientist Training Program$1,706,406
T32 · FY2013 · GM · contact PI
Define the sources of persistent HIV production$402,434
U19 · FY2013 · AI · contact PI
Latent Viral Reservoirs in HIV 1 Infection$264,412
R01 · FY2013 · AI · contact PI
Intermolecular cooperativity in the action of antiviral agents$264,412
R01 · FY2013 · AI · contact PI
Significance of Low Level Viremia in Patients on HAART$228,420
R37 · FY2013 · AI · contact PI
Medical Scientist Training Program$198,618
T32 · FY2013 · GM · contact PI
Medical Scientist Training Program$2,280,705
T32 · FY2012 · GM · contact PI
Define the sources of persistent HIV production$1,241,180
U19 · FY2012 · AI · contact PI
Developmental$702,163
P30 · FY2012 · AI · contact PI
Intermolecular cooperativity in the action of antiviral agents$281,290
R01 · FY2012 · AI · contact PI
Latent Viral Reservoirs in HIV 1 Infection$281,290
R01 · FY2012 · AI · contact PI
Medical Scientist Training Program$248,273
T32 · FY2012 · GM · contact PI
Significance of Low Level Viremia in Patients on HAART$243,000
R37 · FY2012 · AI · contact PI
Medical Scientist Training Program$2,361,024
T32 · FY2011 · GM · contact PI
Define the sources of persistent HIV production$433,692
U19 · FY2011 · AI · contact PI
Latent Viral Reservoirs in HIV 1 Infection$281,290
R01 · FY2011 · AI · contact PI
Intermolecular cooperativity in the action of antiviral agents$281,290
R01 · FY2011 · AI · contact PI
Medical Scientist Training Program$245,940
T32 · FY2011 · GM · contact PI
Significance of Low Level Viremia in Patients on HAART$236,524
R37 · FY2011 · AI · contact PI
Medical Scientist Training Program$2,339,251
T32 · FY2010 · GM · contact PI
Latent Viral Reservoirs in HIV 1 Infection$284,130
R01 · FY2010 · AI · contact PI
Intermolecular cooperativity in the action of antiviral agents$284,130
R01 · FY2010 · AI · contact PI
Significance of Low Level Viremia in Patients on HAART$238,914
R37 · FY2010 · AI · contact PI
Medical Scientist Training Program$146,203
T32 · FY2010 · GM · contact PI
Medical Scientist Training Program$48,734
T32 · FY2010 · GM · contact PI
Medical Scientist Training Program$2,190,922
T32 · FY2009 · GM · contact PI
Intermolecular cooperativity in the action of antiviral agents$287,000
R01 · FY2009 · AI · contact PI
Latent Viral Reservoirs in HIV 1 Infection$287,000
R01 · FY2009 · AI · contact PI
Significance of Low Level Viremia in Patients on HAART$241,326
R37 · FY2009 · AI · contact PI
Medical Scientist Training Program$92,718
T32 · FY2009 · GM · contact PI
Medical Scientist Training Program$46,359
T32 · FY2009 · GM · contact PI
Latent Viral Reservoirs in HIV 1 Infection$39,950
R01 · FY2009 · AI · contact PI
Medical Scientist Training Program$2,214,660
T32 · FY2008 · GM · contact PI
HIV/SIV viral reservoirs in lymphocytes and macrophages$245,461
P01 · FY2008 · MH · contact PI
Significance of Low Level Viremia in Patients on HAART$241,326
R37 · FY2008 · AI · contact PI
Latent Viral Reservoirs in HIV 1 Infection$228,123
R01 · FY2008 · AI · contact PI
Medical Scientist Training Program$46,139
T32 · FY2008 · GM · contact PI
Medical Scientist Training Program$2,023,993
T32 · FY2007 · GM · contact PI
HIV/SIV viral reservoirs in lymphocytes and macrophages$248,733
P01 · FY2007 · MH · contact PI
Significance of Low Level Viremia in Patients on HAART$245,938
R37 · FY2007 · AI · contact PI
Latent Viral Reservoirs in HIV 1 Infection$232,541
R01 · FY2007 · AI · contact PI
Medical Scientist Training Program$2,194,526
T32 · FY2006 · GM · contact PI
SIGNIFICANCE OF LOW LEVEL VIREMIA IN PATIENTS ON HAART$355,043
R01 · FY2006 · AI · contact PI
Latent Viral Reservoirs in HIV 1 Infection$239,487
R01 · FY2006 · AI · contact PI
Project 1: Viral reservoirs in lymphocytes$235,771
P01 · FY2006 · MH · contact PI
Medical Scientist Training Program$2,260,799
T32 · FY2005 · GM
SIGNIFICANCE OF LOW LEVEL VIREMIA IN PATIENTS ON HAART$363,712
R01 · FY2005 · AI
Latent Viral Reservoirs in HIV 1 Infection$245,250
R01 · FY2005 · AI
Project 1: Viral reservoirs in lymphocytes$232,284
P01 · FY2005 · MH
LOW-LEVEL HIV-1 VIREMIA IN PATIENTS ON HAART$55,791
M01 · FY2005 · RR
MEDICAL SCIENTIST TRAINING PROGRAM$2,120,513
T32 · FY2004 · GM
SIGNIFICANCE OF LOW LEVEL VIREMIA IN PATIENTS ON HAART$363,833
R01 · FY2004 · AI
Latent Viral Reservoirs in HIV 1 Infection$245,250
R01 · FY2004 · AI
Project 1: Viral reservoirs in lymphocytes$228,900
P01 · FY2004 · MH
LOW-LEVEL HIV-1 VIREMIA IN PATIENTS ON HAART$117,141
M01 · FY2004 · RR
MEDICAL SCIENTIST TRAINING PROGRAM$2,108,272
T32 · FY2003 · GM
SIGNIFICANCE OF LOW LEVEL VIREMIA IN PATIENTS ON HAART$363,951
R01 · FY2003 · AI
MEDICAL SCIENTIST TRAINING PROGRAM$2,010,424
T32 · FY2002 · GM
SIGNIFICANCE OF LOW LEVEL VIREMIA IN PATIENTS ON HAART$364,065
R01 · FY2002 · AI
HUMAN T CELL RECOGNITION OF HIV ENVELOPE GLYCOPROTEINS$360,043
R37 · FY2002 · AI
LATENT VIRAL RESERVOIRS IN HIV1 INFECTION$307,288
R01 · FY2002 · AI
HIV1 IMMUNIZATION AND LATENT RESERVOIRS IN HAART PATIENT$0
P01 · FY2002 · AI
MEDICAL SCIENTIST TRAINING PROGRAM$1,910,200
T32 · FY2001 · GM
CYTOLYTIC T CELL RESPONSE IN AIDS VACCINE RECIPENTS$354,223
R01 · FY2001 · AI
HUMAN T CELL RECOGNITION OF HIV ENVELOPE GLYCOPROTEINS$351,512
R37 · FY2001 · AI
LATENT VIRAL RESERVOIRS IN HIV1 INFECTION$299,469
R01 · FY2001 · AI
HIV1 IMMUNIZATION AND LATENT RESERVOIRS IN HAART PATIENT$0
P01 · FY2001 · AI
MEDICAL SCIENTIST TRAINING PROGRAM$1,832,440
T32 · FY2000 · GM
CYTOLYTIC T CELL RESPONSE IN AIDS VACCINE RECIPENTS$426,075
R01 · FY2000 · AI
HUMAN T CELL RECOGNITION OF HIV ENVELOPE GLYCOPROTEINS$343,233
R37 · FY2000 · AI
LATENT VIRAL RESERVOIRS IN HIV1 INFECTION$291,875
R01 · FY2000 · AI